Clinical Trial Update: Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating anlotinib hydrochloride plus toripalimab in unresectable or metastatic undifferentiated pleomorphic sarcoma (UPSC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Di Wu | Conditions: Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Status: UNKNOWN